olpasiran: Clinical Trials

3 trials of olpasiran, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Active not recruiting 1

Follow olpasiran: new trials by email Literature Review of olpasiran trials Research Report on olpasiran

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Olpasiran, Placebo - Cardiovascular Disease
Phase 3RecruitingAmgen4062026-03-232026-04-16
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
Olpasiran, Placebo - Cardiovascular Disease
Phase 3RecruitingAmgen110002025-08-222026-11-16
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Placebo, Olpasiran - Atherosclerotic Cardiovascular Disease
Phase 3Active not recruitingAmgen72972022-12-142026-10-27

Conditions studied

Cardiovascular Diseases (2)  ·  Atherosclerosis (1)  ·  Coronary Disease (1)  ·  Myocardial Infarction (1)

Sponsors

Amgen (3)

Countries

Australia (3)  ·  China (3)  ·  United States (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Spain (2)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Estonia (1)

Results publications

PMID 38415744, PMID 38682459, PMID 39322524, PMID 39329200, PMID 41329869, PMID 41841810